Procedures for Exchange of Disease Field. Prior to the replacement of any Time-Limited Exclusive Disease Field or Non-Exclusive Disease Field pursuant to Section 2.2.1 or Section 2.2.2, Genocea shall deliver a written notice to Isconova stating the Disease (the “Exchange Field Candidate”) with which Genocea would like to replace a Disease that, at the time, then underlies a Time-Limited Exclusive Disease Field or Non-Exclusive Disease Field, as the case may be, (“Disease Field Exchange Request”). Following a Disease Field Exchange Request, the procedures for selecting Time-Limited Exclusive Option Fields in Section 2.1.2(a) and Non-Exclusive Option Fields in Section 2.1.3(a), as the case may be, will apply with necessary changes (mutatis mutandis). For this purpose, such provisions shall be applied by treating all references in such sections to the “Time-Limited Exclusive Option Field Candidate” and the “Non-Exclusive Option Field Candidate”, respectively, as though they were references to the Exchange Field Candidate referenced in the Disease Field Exchange Request.
Appears in 3 contracts
Samples: License and Collaboration Agreement (Genocea Biosciences, Inc.), License and Collaboration Agreement (Genocea Biosciences, Inc.), License and Collaboration Agreement (Genocea Biosciences, Inc.)
Procedures for Exchange of Disease Field. Prior to the replacement of any Time-Time- Limited Exclusive Disease Field or Non-Exclusive Disease Field pursuant to Section 2.2.1 or Section 2.2.2, Genocea shall deliver a written notice to Isconova stating the Disease (the “Exchange Field Candidate”) with which Genocea would like to replace a Disease that, at the time, then underlies a Time-Limited Exclusive Disease Field or Non-Exclusive NonExclusive Disease Field, as the case may be, (“Disease Field Exchange Request”). Following a Disease Field Exchange Request, the procedures for selecting Time-Limited Exclusive Option Fields in Section 2.1.2(a) and Non-Exclusive Option Fields in Section 2.1.3(a), as the case may be, will apply with necessary changes (mutatis mutandis). For this purpose, such provisions shall be applied by treating all references in such sections to the “Time-Limited Exclusive Option Field Candidate” and the “Non-Exclusive Option Field Candidate”, respectively, as though they were references to the Exchange Field Candidate referenced in the Disease Field Exchange Request.
Appears in 1 contract
Samples: License and Collaboration Agreement (Genocea Biosciences, Inc.)